- Home
- NVT vs ASND Comparison
NVT vs ASND Comparison
Compare NVT & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | ASND |
|---|---|---|
| Founded | 1903 | 2006 |
| Country | United Kingdom | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1B | 12.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NVT | ASND |
|---|---|---|
| Price | $107.76 | $205.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $107.58 | ★ $256.27 |
| AVG Volume (30 Days) | ★ 2.2M | 640.2K |
| Earning Date | 10-31-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 6.36 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,578,600,000.00 | $758,592,045.00 |
| Revenue This Year | $28.70 | $99.74 |
| Revenue Next Year | $14.60 | $79.40 |
| P/E Ratio | $60.23 | ★ N/A |
| Revenue Growth | 21.54 | ★ 97.46 |
| 52 Week Low | $41.71 | $118.03 |
| 52 Week High | $117.52 | $223.19 |
Technical Indicators
Market Signals| Indicator | NVT | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 49.03 |
| Support Level | $102.25 | $198.30 |
| Resistance Level | $108.89 | $218.50 |
| Average True Range (ATR) | 3.74 | 9.16 |
| MACD | -0.01 | -0.64 |
| Stochastic Oscillator | 76.57 | 28.05 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.